Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 2/20 | 0.41 |
| ▸ | TXN | P10599 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26049288 | 0.86 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL31393492 | 0.81 | MAPT (0.46) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL576091 | 0.80 | MAPT (0.50) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL29407034 | 0.78 | MAPT (0.48) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| Hydrogen Sulfide SCHEMBL28232924 | 0.78 | MAPT (0.48) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL3895678 | 0.77 | TDP1 (0.40) | SMN1; SMN2MAPTHPGDALDH1A1FBP1 | |
| SCHEMBL576770 | 0.77 | MAPT (0.46) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| Alcohol SCHEMBL28170517 | 0.76 | HPGD (0.67) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL775698 | 0.75 | FBP1 (0.37) | ALDH1A1FBP1TXNMAOAMAOB | |
| SCHEMBL1646234 | 0.75 | MAOA (0.41) | SMN1; SMN2MAPTALDH1A1MAPK1FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122058-A | Preparation method of ink and quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-20030176512-A1 | Asymmetric disulfides and methods of using same | PROLX PHARMACEUTICALS CORPORATION (CA) | 2003-09-18 | — | — | US | claimed |
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-10-31 | — | — | US | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20230310636-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| US-11616253-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-03-28 | — | — | US | disclosed |
| US-20220278370-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-09-01 | — | — | US | disclosed |
| US-11367899-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| CN-1191283-C | Nonconjugated cyclic polyene copolymer, rubber composition, and use | MITSUI CHEMICALS INC (JP) | 2005-03-02 | — | — | CN | disclosed |
| WO-2005007108-A2 | ASYMMETRIC DISULFIDES AND METHODS OF USING SAME | PROLX PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040116496-A1 | Asymmetric Disulfides and methods of using same | PROLX PHARMACEUTICALS CORP. | 2004-06-17 | — | — | US | disclosed |
| US-20030176512-A1 | Asymmetric disulfides and methods of using same | PROLX PHARMACEUTICALS CORPORATION (CA) | 2003-09-18 | — | — | US | disclosed |
| US-6552060-B1 | Inhibits abnormal cellular proliferation and restores or prevents inhibition of cellular apoptosis | PROLX PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
| CN-1327454-A | Unconjugated cyclopolyene copolymer, rubber composition, and use | MITSUI CHEMICALS INC (JP) | 2001-12-19 | — | — | CN | disclosed |
| EP-0644206-A1 | Olefin polymerization catalyst and process for preparing polyolefin | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1995-03-22 | — | — | EP | disclosed |
| US-4020149-A | REACTING HYDROGEN SULFIDE AND SULFUR DIOXIDE IN A DISULFIDE SOLVENT | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1977-04-26 | — | — | US | disclosed |
| US-4020144-A | DISULFIDE SOLVENT | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310636-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | PARP1, PARP11, PARP12 | SMN1; SMN2 2446/4885MAPT 3117/4885HPGD 3517/4885 |
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | SMN1; SMN2 172/4885MAPT 2476/4885HPGD 4500/4885 |
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | SMN1; SMN2 258/4885MAPT 2642/4885HPGD 4357/4885 |
| US-20030176512-A1 | Asymmetric disulfides and methods of using same | PRDX3, PDIA5, PRDX5 | SMN1; SMN2 651/4885MAPT 4328/4885HPGD 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.